Literature DB >> 15653420

HBV reactivation after kidney transplantation.

Annemarie Berger1, Wolfgang Preiser, Hans Georg Kachel, Martin Stürmer, Hans Wilhelm Doerr.   

Abstract

Recent studies suggest that reappearance of hepatitis B surface antigen (HBsAg) and loss of anti-HBs antibodies may be common events in bone marrow recipients and patients with chemotherapy. In this study, we reviewed the virologic laboratory records from kidney recipients. Out of 1512 patients, 228 had been diagnosed with resolved HBV infection (anti-HBc positive, HBsAg negative) but normal liver enzyme levels prior to kidney transplantation. Reappearance of HBsAg after kidney transplantation was observed in two (0.9%) of those patients, which may be attributed to reactivation of a latent infection or to a new HBV infection. In both of the patients, HBV infection may have been reactivated although immunosuppression was just on a low level over the whole period. We conclude that natural immunity to HBV may not protect against reactivation in patients with suppression of the immune system. Periodic follow-up of HBV serology for early diagnosis of reactivation is highly recommended in transplant recipients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653420     DOI: 10.1016/j.jcv.2004.10.006

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  15 in total

Review 1.  Antiviral treatment for chronic hepatitis B in renal transplant patients.

Authors:  Ezequiel Ridruejo
Journal:  World J Hepatol       Date:  2015-02-27

Review 2.  Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

Authors:  L H Calabrese; N N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

Review 3.  Management of patients with hepatitis B who require immunosuppressive therapy.

Authors:  Jessica P Hwang; Anna S-F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-11-19       Impact factor: 46.802

4.  Hepatitis B reactivation after chemotherapy: two decades of clinical research.

Authors:  George K K Lau
Journal:  Hepatol Int       Date:  2008-03-05       Impact factor: 6.047

Review 5.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

Review 6.  Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.

Authors:  Venessa Pattullo
Journal:  World J Hepatol       Date:  2015-05-08

7.  Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

Authors:  Tara N Palmore; Neeral L Shah; Rohit Loomba; Brian B Borg; Uri Lopatin; Jordan J Feld; Farooq Khokhar; Glen Lutchman; David E Kleiner; Neal S Young; Richard Childs; A John Barrett; T Jake Liang; Jay H Hoofnagle; Theo Heller
Journal:  Clin Gastroenterol Hepatol       Date:  2009-07-01       Impact factor: 11.382

8.  Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.

Authors:  Umut Kalyoncu; Ozlem Yonem; Meral Calguneri; Osman Ersoy; Omer Karadag; Ali Akdogan; Sule A Bilgen; Sedat Kiraz; Ihsan Ertenli; Yusuf Bayraktar
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

Review 9.  Viral infection in renal transplant recipients.

Authors:  Jovana Cukuranovic; Sladjana Ugrenovic; Ivan Jovanovic; Milan Visnjic; Vladisav Stefanovic
Journal:  ScientificWorldJournal       Date:  2012-05-02

10.  Management of HBV infection during immunosuppressive treatment.

Authors:  Alfredo Marzano
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-12-22       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.